SHMT2 and cancer: High levels of SHMT2 are associated with poor patient prognosis in several cancers and inhibitors that target both SHMT2 and SHMT1 (which catalyzes the same reaction in the cytoplasm) have shown promising results in initial cellular and mouse studies (Cuthbertson et al., 2021).